Clinical Trial Update: Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating intrathecal pemetrexed for leptomeningeal metastasis in EGFR-mutant non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis
• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed (pemetrexed)

Snippet

Sponsor: Taipei Veterans General Hospital, Taiwan | Conditions: Carcinoma, Non-Small-Cell Lung, Epidermal Growth Factor Receptor | Phase 2 | Status: RECRUITING